Search

888 443 3311
    Clarient facebook  Clarient Twitter
MMR Panel by IHC (MLH1, MSH2, MSH6, PMS2)
Alternative Name(s)
Mismatch Repair by IHC, Lynch Syndrome Testing
Methodology
IHC
Specimen Requirements
To perform IHC testing, we request formalin-fixed, paraffin-embedded tissue samples. Please ensure that the blocks are clearly labeled with the patient name or identifier, date of birth and type of sample (tumor, normal). Additionally, a copy of the pathology report accompanying the tissue block will be very helpful. If tissue blocks are not available, we will also accept unstained slides (please submit 1-2 slides per antibody to be tested, cuts must be 4 microns thick).
Clinical Significance
A well-defined subtype of colorectal cancer (CRC) is characterized by a deficiency in the mismatch repair (MMR) pathway. MMR deficiency not only contributes to the pathogenesis of a large proportion of CRC, but also determines the response to many of the drugs that are frequently used to treat this disease.1 Immunohistochemistry (IHC) for MLH1, MSH2, MSH6, and PMS2 protein expression and microsatellite instability (MSI) are well-established tools to screen for Lynch syndrome (LS).2
CPT Code(s)
88342 (qualitative IHC) or 88360 (quantitative/semi-quantitative – manual) or 88361 (quantitative/semi-quantitative – computer assisted).
The listed CPT codes are for reference only. These codes should not direct client billing practices and may not accurately reflect current Clarient billing practices. The listed CPT codes are for reference use only. These codes should not direct billing practices and may not accurately reflect current Clarient billing practices.
Turnaround Time
24 - 48 Hours
References
Turnaround Time: 24 - 36 hours (Technical) and 48 hours (Global)

1. Hewish, M. et al. Nat. Rev. Clin. Oncol. 7, 197–208 (2010); published online 23 February 2010; doi:10.1038/nrclinonc.2010.18. 2. J Clin Oncol 30:1058-1063. © 2012 by American Society of Clinical Oncology